Department of Hematology, Oncology, and Pneumology
University Medical Center
Johannes Gutenberg-University of Mainz
“Histomorphological and molecular diversity of urothelial carcinoma and precursor lesions“
Institute of Pathology
Universitätsklinikum Erlangen & FAU Erlangen-Nürnberg
“The innate host response to BK polyomavirus infections drives APOBEC3-mutagenesis in bladder cancer initiation”
Kidney Research UK Intermediate Fellow
Jack Birch Unit for Molecular Carcinogenesis
Department of Biology & York Biomedical Research Institute
University of York
UK
“Spatial epigenetic-metabolic interplay in Bladder Cancer: A novel perspective on tumor progression and therapy”
Institute of Pathology
University Medical Center Freiburg
“New combination therapies to overcome resistance in bladder cancer”
Klinik für Urologie, Forschungslabor, AG Harnblasenkarzinom
Universitätsklinikum Düsseldorf
Germany
“T cell subset approach to identify immune consequences in ARID1A and KDM6A deficient urothelial carcinoma“
Department of Medicine I
Hematology, Oncology, and Stem-Cell Transplantation
University Medical Center Freiburg
“Epigenetic and Genetic Causes of Differential FGFRi Resistance Despite Identical FGFR3 Aberrations in Bladder Cancer“
Division of Cancer Research
Department of Thoracic Surgery
University Medical Center Freiburg
“Translational approaches to improve diagnostic and therapeutic strategies for bladder cancer”
Institute of Pathology
Oncological Pathology Group
Hospital of the RWTH Aachen University
“Precision medicine in bladder cancer: trials and tribulations on the path to clinical implementation”
Chairman of Clinical Urology
Spitalzentrum Biel
Switzerland
“UcarE’s Pre-clinical Translation Platform”
Clinic of Internal Medicine I,
Haematology, Oncology and Stem Cell Transplantation
University Medical Center Freiburg
Department of Urology
University Medical Center Freiburg
“KMT9 in bladder cancer – an actionable target?”
AG Schüle
Department of Urology
University Medical Center Freiburg